Signed in as:
filler@godaddy.com
Signed in as:
filler@godaddy.com
CT: computed tomography; CTEPH: chronic thromboembolic pulmonary hypertension; DLCO: diffusing capacity of the lung for Carbon Monoxide; PAH: Pulmonary arterial hypertension; PH: pulmonary hypertension. aClass of recommendation. level of evidence. reference(s) supporting recommendations.
WHO Group 2 includes PH due to left heart disease. In this group of PH, the arteries and lungs are not as thick or stiff as WHO Group 1, but there are problems with how the heart squeezes or relaxes, or problems with the valves on the left side of the heart. Because of this, the left heart is unable to keep up with the blood returning from the lungs — causing a “backup” of blood which raises pressure in the lungs. WHO Group 2 is the most common form of PH.
COPD: chronic obstructive pulmonary disease; CTEPH: chronic thromboembolic pulmonary hypertension; DPG: diastolic pressure gradient; LHD: left heart disease; LV: left ventricular; PE: pulmonary embolism; PH: pulmonary hypertension; PVR: pulmonary vascular resistance. aClass of recommendation. level of evidence. reference(s) supporting recommendations.
WHO Group 3 includes PH due to Chronic Lung disease and/or hypoxia (low oxygen levels). These lung diseases include obstructive lung disease where the lung airways narrow and make it harder to exhale (e.g. COPD or emphysema); restrictive lung disease in which the lungs have a tough time expanding when one inhales (e.g. interstitial lung disease or pulmonary fibrosis); sleep apnea; and living in an area of high altitude for a long period of time. Arteries in the lungs tighten so that blood can only go to areas of the lungs that are receiving the most air and oxygen. This tightening leads to high blood pressure throughout the lungs.
CTEPH: chronic thromboembolic pulmonary hypertension; PAH: pulmonary arterial hypertension; PH: pulmonary hypertension; RHC: right heart catheterization. aClass of recommendation. level of evidence. reference(s) supporting recommendations. this recommendation does not apply to patients with end-stage lung disease who are not considered candidates for lung transplantation.
WHO Group 4 is called chronic thromboembolic pulmonary hypertension (CTEPH). CTEPH can occur when the body is not able to dissolve a blood clot in the lungs. This can lead to scar tissue in the blood vessels of the lungs, which blocks normal blood flow and makes the right side of the heart work harder. This type of PH is unique because it can potentially be cured through pulmonary thromboendarterectomy (PTE) surgery to remove the blood clots. However, not all CTEPH patients are eligible for this surgery. A drug is also available for CTEPH patients if a doctor determines that a patient is not a candidate for the PTE surgery or if PH remains after the surgery.
BPA: balloon pulmonary angioplasty; CTEPH: chronic thromboembolic pulmonary hypertension; PAH: pulmonary arterial hypertension; PE: pulmonary embolism; PEA: pulmonary endarterectomy. aClass of recommendation. level of evidence. reference(s) supporting recommendations.
WHO Group 5 is where PH is secondary to other diseases in ways that are not well understood. These associated conditions include, but are not limited to, sarcoidosis, sickle cell anemia, chronic hemolytic anemia, splenectomy (spleen removal) and certain metabolic disorders.
CTD: connective tissue disease; CTEPH: chronic thromboembolic pulmonary hypertension; DPAH: drug-induced pulmonary arterial hypertension; HPAH: heritable pulmonary arterial hypertension; IPAH: idiopathic pulmonary arterial hypertension; PAH: pulmonary arterial hypertension; PEA: pulmonary endarterectomy. aClass of recommendation. level of evidence. reference(s) supporting recommendations.
Copyright © 2022 PULMONARY HYPERTENSION INDIA - All Rights Reserved.
Powered by Delhi Child Heart Center
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.